Verona Pharma amends severance plan contingent on closing of Merck acquisition

Verona Pharma plc

Amendment extends post-change-in-control termination window from 12 to 24 months.
Minimum severance period increased from 3 months to 6 months for eligible employees.
Amendment is void if Transaction Agreement with Merck Sharp & Dohme is terminated.
Effective immediately prior to closing of the pending acquisition (announced July 8, 2025).
Revision to 'Qualifying Resignation' includes completion of knowledge transfer requests.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.